4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	133.53	149.34	249.11	52.35	153	276.73
Short-Term Investments	187.91	275.54	39.12	161.2	94.78	-
Cash & Short-Term Investments	321.44	424.88	288.23	213.55	247.78	276.73
Cash Growth	-38.88%	47.41%	34.97%	-13.81%	-10.46%	457.33%
Accounts Receivable	-	-	-	-	0.05	1.49
Other Receivables	-	-	-	-	0.7	-
Receivables	-	-	-	-	0.75	1.49
Prepaid Expenses	11.13	10.06	8.36	6.96	7.76	4.44
Total Current Assets	332.57	434.93	296.59	220.51	256.28	282.66
Property, Plant & Equipment	39.12	40.61	31.67	35.35	28.95	5.07
Long-Term Investments	137	80.58	10.95	4.91	67.65	-
Other Long-Term Assets	7.04	4.26	0.68	1.08	0.6	0.6
Total Assets	515.73	560.38	339.89	261.85	353.49	288.33
Accounts Payable	4.15	4.39	3.52	3.32	4.76	1.79
Accrued Expenses	16.2	18.87	12.01	8.87	7.74	8.37
Current Portion of Leases	5.68	5.64	3.15	2.66	1.23	-
Current Unearned Revenue	0.87	0.26	0.27	0.88	2.6	6.59
Total Current Liabilities	26.9	29.15	18.95	15.73	16.34	16.74
Long-Term Leases	18.17	18.97	11.52	13.47	15.22	-
Long-Term Unearned Revenue	0.43	1.06	0.97	1.08	2.49	13.23
Other Long-Term Liabilities	0.5	0.6	0.62	0.23	0.33	1.97
Total Liabilities	46.01	49.78	32.06	30.51	34.38	31.94
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	1,094	1,087	723.14	547.02	526.52	392.06
Retained Earnings	-624.17	-576.2	-415.33	-314.49	-207	-135.68
Comprehensive Income & Other	0.33	0.23	0.02	-1.2	-0.42	-
Total Common Equity	469.72	510.61	307.83	231.34	319.11	256.39
Shareholders' Equity	469.72	510.61	307.83	231.34	319.11	256.39
Total Liabilities & Equity	515.73	560.38	339.89	261.85	353.49	288.33
Total Debt	23.85	24.61	14.67	16.12	16.45	-
Net Cash (Debt)	434.59	480.85	284.52	202.34	298.98	276.73
Net Cash Growth	-24.38%	69.01%	40.61%	-32.32%	8.04%	457.33%
Net Cash Per Share	7.82	8.91	7.27	6.25	10.78	43.03
Filing Date Shares Outstanding	46.32	46.3	49.78	33.23	32.24	26.69
Total Common Shares Outstanding	46.32	45.79	43.08	32.63	32.22	26.68
Working Capital	305.67	405.78	277.64	204.78	239.94	265.91
Book Value Per Share	10.14	11.15	7.15	7.09	9.90	9.61
Tangible Book Value	469.72	510.61	307.83	231.34	319.11	256.39
Tangible Book Value Per Share	10.14	11.15	7.15	7.09	9.90	9.61
Machinery	17.57	17.17	14.61	12.61	7.12	5.85
Construction In Progress	1.05	1.18	0.55	0.48	10.07	0.54
Leasehold Improvements	17.76	17.76	16.9	16.9	2.53	2.53

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q